Prematurity of 23 or less weeks' gestation is a risk for transient late-onset hyperglycemia in neonate

Takeru Yamauchi¹⁾, Kei Takasawa¹⁾, Manabu Sugie²⁾, Masatoshi Imamura²⁾, Atsuko Taki¹⁾, Kenichi Kashimada¹⁾


- 1) Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
- 2) Department of Neonatology, Tsuchiura Kyodo General Hospital, Ibaraki, Japan

Take Home Message



Transient hyperglycemia of preterm infants

- \succ Transient hyperglycemia is common among very low birth weight infants (LBWI) ¹⁾.
- Occasionally, we experienced atypical transient hyperglycemia that is prolonged and severer than "classical" transient hyperglycemia.
 - >> A different form of neonatal hyperglycemia?



Aim of this study

Identifying risks and clinical features of prolonged hyperglycemia

Clinical features of Prolonged Hyperglycemia


Duration: > 6 weeks Treatment: required aggressive insulin infusion therapy

	"Classical" hyperglycemia		Prolonged hyperglycemia		<i>P</i> value	
	Median	(25-75 %tile)	Median	(25-75 %tile)	. varac	
Total days with hyperglycemia	3.0	(2-4)	47.5	(21.7-63.0)	<0.001	
Maximum duration (days)	2	(2-3)	44	(17-56)	<0.001	
Age at remission (corrected GA)	27w1d	(25w6d-27w6d)	30w1d	(29w3d-33w0d)	<0.001	
Insulin therapy	4 (23%)		7 (87%)		0.007	
			Fisc	Fischer's exact test Mann-Whitney II-test		

rischer's exact test, Mann-Whitney U-test

Method

- > Study population: Extremely preterm infants (<28weeks) admitted to a single Neonatal Intensive Care Unit in Japan
- ➤ Duration From Apr. 2015 To Mar. 2018
- ➤ Method: Retrospective analysis based on medical records



- Prolonged hyperglycemia: prolonged more than 1-2 wks + persistent after withdraw of parenteral nutrition
- Hyperglycemia: More than 180 mg/dL (10mmol/L) of preprandial glucose levels was sequentially demonstrated twice or more

Exacerbated after the transition from parenteral to enteral nutrition

	At the peak of	"Classical" hyperglycemia		Prolonged hyperglycemia		. <i>P</i> value
hyperglycemia	Median	(25-75 %tile)	Median	(25-75 %tile)	Varo	
	Age (day)	5.0	(4-7)	15.5	(9.7-17.5)	<0.001
	Blood sugar level (mg/dl)))	(241-304)	461	(415-499)	0.007
	Glucose infusion rate (mg/kg/min)	5.7	(4.3-6.6)	0.7	(0-2.3)	0.008
	Enteral feeding (ml/kg/day)	75 ()	(7-38)	114.5	(93.2-127.5)	0.010
	Mann-Whitney I Ltes					

Mann-Whitney U-test

Risks of Prolonged Hyperglycemia


Risks: Extreme preterm (GA≦23W), and lower birth weight

	Classical hyperglycemia		Prolonged hyperglycemia		<i>P</i> value
	Median	(25-75 %tile)	Median	(25-75 %tile)	
Gestational weeks	26w1d	(24w0d-27w0d)	23w3d	(23w2d-23w4d)	<0.001
Birth weight (g)	765	(615-837)	595.5	(546-619)	<0.001
SGA	35%		0%		0.064

Fischer's exact test, Mann-Whitney U-test

Not significant: maternal antenatal steroid administration, intravenous glucose/amio acid/ fat infusion rate, catecholamine / steroid / caffeine administration,

Cut off value to predict prolonged hyperglycemia: 23w5d



Discussion

- Based on our observation, we propose a novel type of transient neonatal hyperglycemia, "Transient prolonged hyperglycemia in neonates (TPHN)"
- It is chracterized by
 - 1. Persistent more than 6 weeks
 - 2. Prolonged after the transition from parenteral to enteral nutrition
 - 3. Requires aggressive treatment, such as insulin infusion.
- Risk factor: Extremely Preterm (23w5d or less)

Reference

- [1] Hays et al. Pediatrics 2006; 118(5): 1811-1818
- [2] Meetze et al. Biol Neonate 1998; 74: 214-21
- [3] Mola-Schenzle et al. Arch Dis Child Fetal Neonatal Ed 2015; 100: F126-F131
- [4] Beardshall et al. J of Paediatrics 2010; 157(5): 715-719

A possible hypothesis for TPHN pathophysiology

Risks for "classical hyperglycemia" Extremely preterm birth (=<23W5D) Maturation delay of Insulin resistance Low Insulin secretion glucose metabolism^{3),4)} **TPHN** Hyperactivation of (severer form of neonatal gluconeogenesis hyperglycemia) Therapeutic agent

- Possible reasons why few studies reported TPHN to date
- Limited number of viable neonates who were born 23w or less of gestation
- As improving viability of extreme preterm infants (=<23w), the number of neonates with TPHN will increase.
 - → More detailed multicenter-studies are required



(catecholamine, steroid)



